Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.
Off-patent medicines must become the “focal point” of health systems around the world as they implement policies to help the recovery from the COVID-19 pandemic, Medicines for Europe and the International Generic and Biosimilar medicines Association have urged.
Speaking as the two industry associations held their joint annual conference in Athens, Greece, in early October, Medicines for Europe and the IGBA insisted that the “smart use of off-patent medicines
As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.
